iTeos Posts New Preclinical Data For Anti-TIGIT Antibody At ASH 2021

Comments
Loading...

ITeos Therapeutics Inc ITOS posted new preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the American Society of Hematology (ASH) Annual Meeting & Exposition and the TIGIT Therapies Digital Summit 2021.

  • Data at the ASH 2021 demonstrated the efficacy of EOS-448 as a single agent and in combination with an immunomodulatory imide drug (IMiD) in a preclinical model of multiple myeloma. 
  • The Fc-enabled anti-TIGIT monoclonal antibody elicited effective control of multiple myeloma disease progression, while an Fc-disabled version was inactive.
  • Furthermore, the Fc-enabled anti-TIGIT antibody demonstrated synergistic activity when combined with an IMiD.
  • Preclinical data shared at TIGIT Therapies Digital Summit highlight evidence for a multifaceted mechanism of action of EOS-448.
  • "We look forward to progressing our clinical development plan in 2022 in both multiple myeloma and solid tumors with several combinations," said Michel Detheux, President & CEO.
  • Related Link: iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK.
  • Price Action: ITOS closed 1.38% lower at $34.26 on Thursday.
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!